GIG CYMRU NHS WALES | Cyd-bwyllgor Comisiynu Joint Commissioning Committee

Agenda Item
4.4

Quality, Safety and Outcomes Sub-Committee

Standard Operating Procedure | Medicines Optimisation: Process for Blueteq Form Development

Dyddiad y Cyfarfod / Date of Meeting	29/06/2026
Statws Cyhoeddi / Publication Status	Open/ Public
	Not Applicable
Awdur yr Adroddiad / Report Author	Owen Campbell, Medicines Optimisation Support Manager, Rajiv Pandya, Advances Medicines Optimisation Pharmacist
Cyflwynydd yr Adroddiad / Report Presenter	Angharad Lawson, Principal Medicines Optimisation Pharmacist
Noddwr Gweithredol yr Adroddiad / Report Executive Sponsor	Iolo Doull, Medical Director

Pwrpas yr Adroddiad / Report Purpose	For Approval For Assurance

Committee / Group / Individuals	Date	Outcome
N/A	Click or tap to enter a date.	Choose an item.

1. SITUATION / BACKGROUND

Blueteq® is used across NHS Wales to support the commissioning, monitoring and reimbursement of high-cost and specialist medicines. For medicines commissioned by the NHS Wales Joint Commissioning Committee (NWJCC), Blueteq® forms ensure prescribing aligns with agreed commissioning policies, national guidance (e.g. NICE, AWMSG) and defined eligibility criteria.

In the past there has been variation in how Blueteq® forms are developed, reviewed and implemented within the Medicines Optimisation team. As the meds optimisation team becomes more established and grows, this has created a need for a standardised, transparent and auditable process to ensure consistency, clinical accuracy, and robust governance throughout the form lifecycle (development, amendment and removal).

The proposed Standard Operating Procedure (SOP) sets out a structured process for Blueteq® form development, including defined roles and responsibilities for each team member, version control, clinical validation and governance steps prior to forms going live.

2. ASSESSMENT

The introduction of this SOP will strengthen governance and quality assurance arrangements for NWJCC-commissioned medicines by ensuring that all Blueteq® forms:

- Are consistently developed using a standardised process aligned to national guidance and commissioning policies
- Undergo appropriate clinical review and specialist input prior to implementation
- Maintain robust version control and auditability across the development lifecycle
- Support equitable patient access through consistent application of eligibility criteria
- Enable effective monitoring, financial control and assurance of high-cost medicines use

Overall, the SOP provides a clear and reproducible framework that reduces variation, mitigates risk of error, and supports safe, evidence-based and cost-effective use of commissioned medicines across NHS Wales

3. RECOMMENDATIONS

The members of the Quality, Safety and Outcomes Sub-Committee are asked to:

- **Approve** this Standard Operating Procedure at Appendix 1 for implementation.

Strategic and Regulatory Assessment

Objectives / Strategy	
Dolen i Amcan (au) Strategol CBC / Link to JCC Strategic Objectives(s)	Maximise Value
	• Ensuring appropriate use of high cost medicines • Improving cost effective prescribing • Reducing duplication • Strengthening financial control and oversight • Supporting data-driven decision making through high quality, consistent data collection, which can inform commissioning decisions and service planning.
Dolen i Ddeddf Llesiant Cenedlaethau'r Dyfodol – Nodau Llesiant / Link to Wellbeing of Future Generations Act – Wellbeing Goals *150623-guide-to-the-fg-act-en.pdf (futuregenerations.wales)*	A Healthier Wales
	If more than one applies please list below: A more equal Wales: Promoting equitable access to medicines – by applying consistent eligibility criteria across Wales, reducing unwarranted variation in access to commissioned treatments.
Dolen i Hwyluswyr Ansawdd *(Canllawiau Statudol Dyletswydd Ansawdd (llyw.cymru)) /* **Link to Enablers of Quality** *(Duty of Quality Statutory Guidance (gov.wales))*	Data to Knowledge
	By ensuring Blueteq® forms capture structured, consistent and high-quality data on the use of high-cost medicines. This enables robust monitoring, reporting, and translation of data into actionable insights to inform commissioning decisions, service planning and continuous improvement.
Dolen i Feysydd Ansawdd *(Canllawiau Statudol Dyletswydd Ansawdd (llyw.cymru)) /* **Link to Domains of Quality** *(Duty of Quality Statutory Guidance (gov.wales))*	Effective
	By embedding a standardised, evidence-based approach to Blueteq® form development, ensuring that commissioned medicines are used appropriately, in line with national guidance and agreed clinical criteria, thereby optimising patient outcomes and resource utilisation.
Effaith Amgylcheddol/ Cynaliadwyedd (5R) /	No - Not Applicable
	If more than one applies please list below:

Environmental /Sustainability Impact (5Rs)	

Impact Assessment		
Ansawdd *Ydych chi wedi ymgymryd â Sgrinio Asesiad o'r Effaith ar Ansawdd? /* **Quality** *Have you undertaken a Quality Impact Assessment Screening?*	Yes: ☐	No: ☒
	Outcome:	If no, please include rationale below: Reporting on quality matters from last JCC meeting.
Cydraddoldeb *Ydych chi wedi ymgymryd â Sgrinio Asesiad o'r Effaith ar Gydraddoldeb? /* **Equality** *Have you undertaken an Equality Impact Assessment Screening?*	Yes: ☐	No: ☒
	Outcome:	If no, please include rationale below: Not applicable to this team specific SOP.
Cyfreithiol / Legal	There are no specific legal implications related to the activity outlined in this report.	
Enw da / Reputational	Yes (Include further detail below)	
	• Demonstrating strong governance and assurance – showing that robust, standardised processes are in place to support safe and consistent decision-making. • Reinforcing credibility and clinical leadership – through alignment with national guidance and incorporation of specialist clinical input. • Supporting transparency and accountability – via clear processes, version control and auditability of Blueteq® form development. • Enhancing stakeholder confidence – including clinicians, health boards and external partners, by ensuring equitable and evidence-based access to commissioned medicines. • Positioning NWJCC as a high-performing commissioning organisation – with clear,	

	reproducible systems that support quality, safety, and effective use of resources.
Effaith Adnoddau *(Pobl /Ariannol) /* **Resource Impact** *(People / Financial)*	There is no direct impact on resources as a result of the activity outlined in this report.
	This does not impact on the current workforce establishment apart from familiarisation during induction processes. No direct additional financial cost associated with implementation.